Minaris Advanced Therapies provides comprehensive plasmid engineering services designed to enhance transgene expression, improve viral vector yield, and reduce development risk from the earliest stages of a program. Backed by deep scientific expertise and a robust plasmid technology portfolio, the team partners with clients to optimize construct performance and strengthen product quality, safety, and manufacturability across the development lifecycle.
Thoughtful plasmid design plays a critical role in successful gene therapy manufacturing. By maximizing transgene control and expression, optimized constructs can significantly improve viral vector yield, scalability, and cost efficiency, while also reducing genome instability and safety risks. Minaris integrates these principles into every program, supporting clients from early discovery through IND-enabling studies and GMP transition with flexible, program-specific.
Clients can choose between ready-to-use proprietary plasmids and custom-engineered constructs. The ready-to-use portfolio includes validated lentiviral (LV), AAV, and adenoviral systems, as well as the SnapFast™ plasmid library, enabling faster initiation of packaging construct development. For programs requiring tailored optimization, custom engineering services align construct design with specific therapeutic and manufacturing goals. Enhancements may include safer WPRE sequences, reduced cryptic splicing, optimized antibiotic marker selection, and integration into SnapFast™ or proprietary backbones to improve overall safety and functionality.
A recent case study demonstrates the impact of this approach. An emerging therapeutics company developing a cystic fibrosis program faced toxicity and mutation challenges with a CFTR construct in E. coli. By suppressing bacterial expression, preventing mutation during cloning, and restoring expression in human cells, Minaris transformed a toxic, unstable construct into a stable and functional solution.
Through integrated expertise and high-performance plasmid design, Minaris Advanced Therapies accelerates development timelines and supports long-term clinical and commercial success.
